Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB has reported that its marketing authorization application for the use of Neupro in the treatment of moderate-to-severe restless legs syndrome has been accepted for filing by the European Medicines Agency.
Subscribe to our email newsletter
The filing is based on the results of two fixed-dose, randomized, double-blind, placebo-controlled efficacy and safety studies that evaluated rotigotine for the treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in approximately 1,000 patients over six months. In these trials, rotigotine produced statistically significant reductions in RLS symptoms compared to placebo and was generally well-tolerated.
Neupro is already approved in Europe and the US for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy and in Europe as adjunctive therapy with levodopa for advanced-stage Parkinson’s disease. Neupro is a once-daily patch designed to provide continuous drug delivery over a 24 hour period.
Troy Cox, president CNS Operations, UCB, said: “This new filing for Neupro reflects UCB’s commitment to finding innovative medicines for conditions where there is a continuing need for alternative treatment.”